Larry Schlossman

A non-opioid designer molecule for treating chronic neuropathic pain by calming hyperactive pain-sensing neurons in the peripheral nervous system has had promising results in a preclinical study.

A promising venture that hopes to develop a new drug therapy for colorectal cancer won $50,000 in funding and recognition from experienced venture capitalists on May 26 at the annual Biomedical Business Plan Challenge.

Eight Weill Cornell Medicine faculty members have been selected for the fifth round of the Daedalus Fund for Innovation awards, a pioneering institutional program that helps advance promising applied and translational research projects and emerging technologies that have commercial potential.

The second annual Dean’s Symposium on Opportunities for Entrepreneurship and Academic Drug Development highlighted the resources available to Weill Cornell Medicine investigators to help them turn their research findings into new treatments and therapies for patients.

Weill Cornell Medicine’s BioVenture eLab, a hub of the institution’s entrepreneurial activity celebrated a milestone on Jan. 23: the official launch of its new name and the opening of its dedicated space at 1157 York Ave.

The goal of the Dean’s Inaugural Symposium on Opportunities for Entrepreneurship and Academic Drug Development, hosted at Weill Cornell Medicine’s Uris Auditorium, was to highlight the resources available to investigators to help them turn their research findings into new treatments and therapies for patients.

Startup Symposium and Poster Session Scheduled for Jan. 26